English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

High-grade gliomas are the most common brain tumors within central nervous system (CNS) neoplasms; they have an average survival of only 18 months, mainly due to their resistance to different therapeutic strategies. To date, the only treatment that has managed to improve in some months the survival of patients with these gliomas is the protocol designed by Stupp et al. (2005), which consists of surgery paired with adjuvant temozolamide (TMZ), and radiotherapy (RT). However, despite prolonging the life of patients up to 18 months, it still lacks a sensitive and/or specific prognostic value. So far, there are only three molecular markers of clinical relevance for this disease; however, the National Institute of Health of the United States, detected a small group of individuals (“exceptional responders”) that 1. Grupo Genética, Regeneración y Cáncer (GRC), Instituto de Biología, Sede de Investigación Universitaria, Universidad de Antioquia, Medellín, Colombia. 2. Grupo de Investigaciones Biomédicas, Facultad de Ciencias de la Salud, Corporación Universitaria Remington, Medellín, Colombia. 3. Instituto de Cancerología-Clínica Las Américas, Medellín, Colombia. 4. Grupo de Ciencias Farmacológicas y Ciencias Básicas, Facultad de Ciencias de la Salud, Área farmacogenómica, CES, Medellín, Colombia. * Autor de correspondencia: <lina.barrera@uniremington.edu.co> Recibido: junio de 2019; aceptado: octubre de 2019. 23 Actual. Biol. Volumen 41 / Número 111, 2019 Barrera-Arenas et al. seem to have a longer survival associated with hypermethylation of the promoter of gene MGMT. Recent studies suggest that in “exceptional responders” there are other genetic factors not yet described involved in DNA damage repair. In this review the use of DNA repair as a biomarker is suggested when patients with high-grade gliomas are treated with genotoxics TMZ and RT. Furthermore, three techniques that allow quantification of the genetic instability of these patients are detailed: detection of Micronuclei (MN) in peripheral blood lymphocytes by Fenech method, detection of MN in peripheral blood reticulocytes by flow cytometry, and Sister Chromatid Exchange (SCE).

Búsqueda de nuevos biomarcadores genéticos en gliomas de alto grado